Imbio algorithms include Lung Texture Analysis, for quantifying lung texture to identify interstitial lung disease and other fibrotic conditions; RV/LV, for identifying increased RV/LV diameter ratio, a sign of short-term mortality and adverse clinical events in patients with various pulmonary vascular diseases; and Airway Analysis, for accurate, repeatable airway measurements.

Additionally, it offers lung density analysis algorithms for detecting signs of emphysema, COPD, consolidation, ground glass, COVID-19, and pneumonia. Certain applications like Lung Density Analysis Inspiration include Imbio Noise Reduction Technology (NRT) to aid quantification and visualization of low-dose scans in cases of emphysema and COPD. The company also has an algorithm for checking calcium build-up in the heart’s arteries.


Invenshure, a venture studio, has spent years building up the company’s portfolio, which includes its XV Scanner. Imbio’s Software as a Service delivery model enables providers to generate XV LVAS and CT LVAS reports from this scanner or existing hospital equipment.

According to Danny Cunagin, chairman of Imbio and co-CEO of Invenshure, the combined platform will “maximize patient impact and shareholder value.”

The companies did not disclose a completion date for the acquisition.

Back to HCB News

CT Homepage